Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atropine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.91 |
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.91 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.91 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.91 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.91 |
| ▸ | LMNA | P02545 | 3/20 | 0.91 |
| ▸ | HTR2C | P28335 | 2/20 | 0.91 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.91 |
| ▸ | BLM | P54132 | 2/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.91 |
| ▸ | MEN1 | O00255 | 1/20 | 0.91 |
| ▸ | POLB | P06746 | 1/20 | 0.91 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.91 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.91 |
| ▸ | HRH1 | P35367 | 1/20 | 0.91 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.91 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atropine SCHEMBL27510472 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL3050622 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL28275981 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Endo-Atropine SCHEMBL29555014 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Hyoscyamine SCHEMBL34273 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL31133 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL2406485 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL31132 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL34274 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL34275 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3366680-B1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES INC (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-3366680-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | Parion Sciences, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180111907-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES, INC. | 2018-04-26 | — | — | US | disclosed |
| EP-2855435-B1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES INC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9878988-B2 | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases | PARION SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160122306-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES, INC. (US) | 2016-05-05 | — | — | US | disclosed |
| US-9260398-B2 | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases | PARION SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150099764-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| EP-2855435-A2 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | Parion Sciences, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8980898-B2 | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases | PARION SCIENCES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2013181232-A2 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | JOHNSON MICHAEL ROSS (US) | 2013-12-05 | — | — | WO | disclosed |
| US-20130324559-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| WO-2011081937-A1 | CORTICOSTEROID-BETA-AGONIST-MUSCARINIC ANTAGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| EP-2294077-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | Gilead Sciences, Inc. (US) | 2011-03-16 | — | — | EP | disclosed |
| WO-2010132743-A1 | CORTICOSTEROID BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010126953-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009152171-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099764-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | SCNN1B, SCNN1A, SCNN1G | CHRM1 434/4885CHRM2 270/4885CHRM3 166/4885 |
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | ADRB1, ADRB2, ADRB3 | CHRM1 74/4885CHRM2 76/4885CHRM3 24/4885 |
| US-20160122306-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | SCNN1B, SCNN1A, SCNN1G | CHRM1 434/4885CHRM2 270/4885CHRM3 166/4885 |
| US-20130324559-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | SCNN1B, SCNN1A, SCNN1G | CHRM1 434/4885CHRM2 270/4885CHRM3 166/4885 |
| US-20180111907-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | SCNN1B, SCNN1A, SCNN1G | CHRM1 434/4885CHRM2 270/4885CHRM3 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.